You are here

NEWS

News-in-brief / 05.28.16

New findings on β-cell proliferation points to regenerative medicine approach to diabetes

By Broad Communications

Loss of pancreatic β-cells or their proper function is characteristic of type 1 and type 2 diabetes, so restoring functional β-cell mass has been a major therapeutic goal in the field. A team led by Bridget Wagner at the Broad Institute's Center for the Science of Therapeutics, working with Broad associate member Rohit Kulkarni’s lab at Joslin Diabetes Center, showed that this may be achievable in humans. They found that the kinase-inhibiting enzyme 5-IT, which is known to promote β-cell mass in rodents, can also spark β-cell proliferation in humans by inhibiting the protein DYRK1A. The research, published in Diabetes, suggests a possible regenerative medicine approach to diabetes.